Both Suboxone (buprenorphine + naloxone) and methadone are FDA-approved medications for opioid use disorder. Both have decades of clinical evidence behind them. Both, when prescribed appropriately, reduce overdose death rates by 50 percent or more compared with no medication. They are not competing brands of the same product — they work through different mechanisms, have different access models, and produce very different daily lives. The right choice depends on your situation, not on which one a particular provider happens to be set up to prescribe.

This is a comparison guide, not a prescription. The decision about which medication is right belongs between you and a medical professional who has actually examined you and reviewed your use history. What this guide does is help you walk into that conversation knowing the right questions to ask.

How They Work

Methadone is a full opioid agonist. It binds to the same mu-opioid receptors in the brain that heroin, oxycodone, fentanyl, and other opioids bind to. Because it is long-acting (24-36 hour half-life), one daily dose is enough to prevent withdrawal and cravings without producing the pronounced highs and lows of short-acting opioids. It does not block the effects of other opioids — taking methadone and then using fentanyl is dangerous because the receptor sites are occupied by methadone but additional opioids still produce respiratory depression.

Suboxone is a combination of buprenorphine (a partial mu-opioid agonist) and naloxone (an opioid antagonist that is mostly inert when the medication is taken correctly). Buprenorphine binds tightly to the same receptors as full opioids, but only partially activates them — this produces a "ceiling effect" where higher doses do not produce more euphoria or more respiratory depression past a certain point. Because of the tight binding, buprenorphine displaces other opioids from receptors; this is what makes it both a treatment for opioid use disorder and the reason it can throw someone into precipitated withdrawal if taken too soon after using a full opioid.

Methadone fills the receptors. Suboxone partially fills them and prevents anything else from getting in. That single difference drives most of the other comparisons in this article.

Access — Where the Real-World Difference Begins

Methadone for opioid use disorder is dispensed only through federally certified Opioid Treatment Programs (OTPs), often called "methadone clinics." There are about 1,900 OTPs in the United States, and they are concentrated in urban areas. Treatment starts with daily in-person visits to the clinic to receive the dose. After a period of stability — typically 90 days to 2 years depending on the program and the patient''s progress — patients earn "take-home doses" that reduce the visit frequency. The clinic schedule controls a significant part of daily life, especially in the early phase.

Suboxone (buprenorphine) can be prescribed by any practitioner with prescriptive authority since the federal MAT Act of 2023 eliminated the prior "X-waiver" requirement. Buprenorphine prescriptions are dispensed at any retail pharmacy. A typical treatment plan involves a doctor''s visit every 1 to 4 weeks, with prescriptions covering the interval. The medication is taken as a sublingual film or tablet that dissolves under the tongue.

Practical implication. If you live in a rural area, work shifts that conflict with clinic hours, or value medical privacy enough to want your treatment to look like any other prescription, Suboxone is usually more accessible. If you are in a city with multiple OTPs and would benefit from the structure of daily clinic visits and integrated wraparound services (counseling, case management, social services), methadone may fit better.

Starting the Medication (Induction)

Methadone induction typically begins at a low dose (10-30mg) and is titrated up over days to weeks until the patient reaches a stable maintenance dose (typically 60-120mg, sometimes higher). It is generally well-tolerated and does not require the patient to be in withdrawal at the time of the first dose.

Suboxone induction is more nuanced because of buprenorphine''s high affinity for the opioid receptor. If someone takes Suboxone while a full opioid agonist is still active on their receptors, the buprenorphine kicks the full agonist off, producing rapid and intense withdrawal — "precipitated withdrawal," which is worse than the withdrawal you would have experienced normally. To avoid this, traditional induction protocols required patients to be in moderate withdrawal (typically 12-72 hours after the last opioid use, depending on what was used) before the first Suboxone dose.

Newer protocols — including "micro-dosing" or the "Bernese method" — allow Suboxone induction without requiring a withdrawal period. The patient starts with very low doses (0.5mg) while still using their current opioid, and the buprenorphine accumulates slowly until it can take over. This is particularly valuable for people transitioning from fentanyl, which lingers in body tissues and makes traditional induction unpredictable. Ask your prescriber about micro-dosing if fentanyl is in your use history.

Daily Life on Each Medication

On methadone: You go to the clinic every morning (or your scheduled time) for the first 90 days at minimum. The clinic typically opens at 5 or 6 a.m. and closes by 11 a.m. You take the dose under observation. You may also have weekly individual or group counseling at the clinic. Once you earn take-homes, frequency drops — often to 6 take-home doses per week after the first year, and 13 or more after extended stability. Side effects are similar to other opioids: constipation, sweating, weight gain, and reduced libido are common; some patients experience sedation that improves with dose adjustment.

On Suboxone: You take a film or tablet once or twice daily, anywhere. You see your prescriber every 1-4 weeks depending on stability. Side effects often include headaches, constipation, nausea (especially during induction), and insomnia. Some patients experience tooth decay associated with the sublingual route; rinsing the mouth with water after the film dissolves is recommended. The "ceiling effect" means lower overdose risk if the medication is taken correctly — but combining Suboxone with benzodiazepines, alcohol, or other sedatives can still cause fatal respiratory depression.

Cost and Insurance

Methadone via an OTP typically costs $80-$120 per week without insurance. The price covers the medication, counseling, and case management bundled together. With insurance (including Medicaid and Medicare), most patients pay $0-$50 per week out of pocket.

Suboxone prescriptions cost $80-$300 per month for the medication, plus the cost of the prescriber visit ($50-$300 per visit depending on whether you see a primary-care provider, specialist, or addiction medicine clinic). Generic buprenorphine/naloxone has lowered the medication price significantly. With insurance, most patients pay $0-$50 per month for the medication. Medicaid covers Suboxone in all 50 states. See [[does-medicaid-cover-drug-rehab|Medicaid coverage of rehab]] for the specifics.

Pregnancy

Both medications are safer for pregnant patients with opioid use disorder than ongoing untreated use, and both are safer than abrupt detoxification (which carries a real risk of fetal demise). Historically, methadone was the standard of care during pregnancy because of decades of safety data. Current guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the American Society of Addiction Medicine (ASAM) now consider buprenorphine equivalent or preferred in most cases — buprenorphine-exposed infants have, on average, milder and shorter neonatal abstinence syndrome (NAS) symptoms than methadone-exposed infants. Either is appropriate; the right choice involves the obstetric team, the patient, and the addiction medicine prescriber.

Side Effects and Drug Interactions

Methadone-specific concerns:

Suboxone-specific concerns:

How Long Do People Stay on MAT?

There is no "correct" duration. The evidence is clear that longer treatment produces better outcomes — people who stay on MAT for 2+ years have significantly lower relapse and mortality rates than those who taper off in the first year. Some people stay on the medication indefinitely, much as someone with hypertension stays on blood pressure medication for life. The framing that taper is the goal is outdated; the framing that MAT is a tool you use for as long as it is helpful is the current standard of care.

If and when tapering is appropriate, it is done slowly under medical supervision. Buprenorphine tapers typically take months to years; methadone tapers are similarly slow. Rushing produces poor outcomes.

Switching Between Them

Patients can switch from Suboxone to methadone (relatively straightforward — the methadone clinic re-stabilizes you) or from methadone to Suboxone (more complex — methadone has a long half-life and must be tapered to a low dose, often 30mg or less, before buprenorphine induction). The transition from methadone to buprenorphine is the harder direction; some treatment programs specialize in it. Discuss with your addiction medicine prescriber rather than attempting to manage it yourself.

Stigma and Identity

Two final notes that matter even though they are not pharmacological:

If you are weighing this decision: write down the practical constraints of your life (where you live, when you work, what your insurance covers, who is in your support system), bring that list to an addiction medicine clinician, and ask them to recommend a starting point. The choice is rarely about which medication is theoretically better; it is about which one fits your life well enough that you will stay on it long enough to recover. Read [[medication-assisted-treatment-guide|the full MAT guide]] for the broader context including naltrexone, the third FDA-approved option.